NanoViricides, Inc. (NYSE American: NNVC) presented its latest advancements at the MicroCap <a target=_blank href= ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

The global coronavirus therapeutics market is projected to exceed $16 billion by 2031. With its patented sublingual interferon technology, Ainos is poised to redefine antiviral treatment standards, ...

NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization (“CRO”) to conduct a Phase II clinical trial for ...

1. Treatment: Proven broad-spectrum antiviral efficacy against multiple coronavirus variants. 2. Prevention: Potential to strengthen immune defenses and reduce susceptibility to new infections.

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 12.79%, which has investors questioning if this is right ...

Dr. Gabriela Andujar Vazquez, with Dartmouth Health, is answering viewer questions as winter illnesses continue to spread.

Discover which therapies are expected to grab the major dry eye disease market share @ Dry Eye Disease Market Report Dry eye disease (DED) is a common chronic condition characterized by inadequate ...